Preclinical
Karolinska Development’s portfolio company Aprea presents results from studies with APR-246 in combination with immune checkpoint blockade.
3D co-cultured healthy cells survive in method for evaluation of TCR efficacy and toxicity
The American Association for Cancer Research (AACR) Annual Meeting is taking place in Atlanta. Here’s a look at just a few stories coming out of the meeting.
Since Biogen and Tokyo-based Eisai recently reported a massive failure in Alzheimer’s research for their drug aducanumab, scientists and industry watchers are scanning the tea leaves looking for other potential approaches to treating the disease. One that is of interest is a hormone called Klotho.
Activity Demonstrated as a Single Agent and in Combination with an anti-PD-1 antibody
Bone marrow transplants are both incredibly risky as well as expensive procedures. Nonetheless, they are still effective and have been used by doctors since the 1950s, with many successful procedures completed over the years.
While this type of personalized therapy is revolutionizing cancer treatment and healthcare, it has some formidable limitations.
Today, Cyclerion has been launched on the second floor of a 200,000-square-foot , 3-story space on Binney Street, in Cambridge.
The American Association for Cancer Research (AACR) Annual Meeting is ongoing in Atlanta, with plenty of companies presenting interesting and cutting-edge science. Here’s a look at just a representative few.
Novartis will pay $310 million upfront for the Boston-based inflammation company IFM Tre. IFM TRE is very much an early-stage company, with one compound, IFM-2427, in an early Phase I clinical trial, and two preclinical assets.
PRESS RELEASES